These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18178783)

  • 1. Does lowering of blood glucose improve cardiovascular morbidity and mortality?
    Iqbal N; Rubenstein AH
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):163-7. PubMed ID: 18178783
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intensive blood glucose lowering to reduce cardiovascular risk: contra].
    Marx N
    Dtsch Med Wochenschr; 2009 May; 134(20):1061. PubMed ID: 19421930
    [No Abstract]   [Full Text] [Related]  

  • 3. [Intensive blood glucose lowering to reduce cardiovascular risk: pro].
    Martin S
    Dtsch Med Wochenschr; 2009 May; 134(20):1060. PubMed ID: 19421929
    [No Abstract]   [Full Text] [Related]  

  • 4. [World news in age-related diabetes: blood sugar lowering can improve prognosis].
    Einecke D
    MMW Fortschr Med; 2005 Sep; 147(38):1. PubMed ID: 16218218
    [No Abstract]   [Full Text] [Related]  

  • 5. [Is an intensive glycaemic control beneficial in diabetes type 2?].
    Martin S
    Dtsch Med Wochenschr; 2011 Sep; 136(39):1940. PubMed ID: 21948602
    [No Abstract]   [Full Text] [Related]  

  • 6. Does intensive glycemic control improve cardiovascular outcomes?
    Pendergrass M
    Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):529. PubMed ID: 18806805
    [No Abstract]   [Full Text] [Related]  

  • 7. Diabetes as a 'cardiovascular disease equivalent': implications for treatment.
    Laakso M
    Nat Clin Pract Cardiovasc Med; 2008 Nov; 5(11):682-3. PubMed ID: 18797431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The joint effects of different types of glucose-lowering treatment and duration of diabetes on total and cardiovascular mortality among subjects with type 2 diabetes.
    Khalangot M; Tronko M; Kravchenko V; Kulchinska J; Hu G
    Diabetes Res Clin Pract; 2008 Oct; 82(1):139-47. PubMed ID: 18703252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular disease and intensive glucose lowering in type 2 diabetes.
    Younis N; Soran H; Hassanein M
    QJM; 2009 Apr; 102(4):293-6. PubMed ID: 19147659
    [No Abstract]   [Full Text] [Related]  

  • 10. Intensive glucose control in type 2 diabetes.
    Parashar A
    N Engl J Med; 2008 Oct; 359(14):1520; author reply 1520-1. PubMed ID: 18837128
    [No Abstract]   [Full Text] [Related]  

  • 11. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
    Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
    Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glycemic control and cardiovascular diseases in type 2 diabetes].
    Madsbad S
    Ugeskr Laeger; 2008 Nov; 170(45):3634. PubMed ID: 18986612
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2016 Sep; 105(20):1221-1222. PubMed ID: 27705192
    [No Abstract]   [Full Text] [Related]  

  • 16. Follow-up of intensive glucose control in type 2 diabetes.
    Mühlhauser I
    N Engl J Med; 2009 Jan; 360(4):417; author reply 418. PubMed ID: 19172674
    [No Abstract]   [Full Text] [Related]  

  • 17. Metformin: diamonds are forever.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieve better glucose control for your hospitalized patients.
    Woolever DR
    J Fam Pract; 2008 Dec; 57(12):782-8. PubMed ID: 19080760
    [No Abstract]   [Full Text] [Related]  

  • 19. Glucokinase activators in diabetes management.
    Coghlan M; Leighton B
    Expert Opin Investig Drugs; 2008 Feb; 17(2):145-67. PubMed ID: 18230050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment.
    Gore MO; McGuire DK
    Diab Vasc Dis Res; 2012 Apr; 9(2):85-8. PubMed ID: 22496441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.